Akero Therapeutics, Inc. (NASDAQ:AKRO) saw its share prices surge by 16.33% on Thursday, closing at $54.08 apiece following news of a $5.2 billion merger with Novo Nordisk. The deal includes a $54 offer price per share and a contingent value right (CVR) tied to a milestone achievement. Each shareholder will receive $6 upon full US regulatory approval of efruxifermin by June 30, 2031, representing a 19% premium over the 30-day VWAP. Akero Therapeutics’ EFX program for MASH treatment complements Novo’s expertise in GLP-1-based metabolic therapies. While AKRO shows potential, some AI stocks may offer higher returns with lower risk. For more information on promising AI stocks, check out our free report on the best short-term AI stock.

Read more at Yahoo Finance: Akero Therapeutics (AKRO) Jumps 16% on $5.2-Billion Novo Nordisk Merger